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Abstract
Although a growing number of studies suggest interactions between Schistosoma parasites
and viral infections, the effects of schistosome infections on the host response to viruses
have not been evaluated comprehensively. In this systematic review, we investigated how
schistosomes impact incidence, virulence, and prevention of viral infections in humans and
animals. We also evaluated immune effects of schistosomes in those coinfected with
viruses. We screened 4,730 studies and included 103. Schistosomes may increase suscep-
tibility to some viruses, including HIV and Kaposi’s sarcoma-associated herpesvirus, and
virulence of hepatitis B and C viruses. In contrast, schistosome infection may be protective
in chronic HIV, Human T-cell Lymphotropic Virus-Type 1, and respiratory viruses, though
further research is needed. Schistosome infections were consistently reported to impair
immune responses to hepatitis B and possibly measles vaccines. Understanding the inter-
play between schistosomes and viruses has ramifications for anti-viral vaccination strate-
gies and global control of viral infections.
Author summary
Many studies have described the effects of parasitic Schistosoma worm infections on the
way that humans and animals respond to a variety of viral infections. Our goal was to eval-
uate, in a systematic manner, how having a schistosome parasitic infection affects a host’s
susceptibility to viral infections, the clinical disease course of viral infections, and preven-
tion of viral infections by vaccines. We also assessed the effects of schistosome infection
on the host immune response to viruses. We screened 4,730 studies for potential relevance
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and included 103 of them in this review. Overall, our analysis showed that schistosome
infection impairs the host response to many viruses. This includes increasing host suscep-
tibility to HIV and possibly Kaposi’s sarcoma-associated herpesvirus, worsening the sever-
ity of clinical disease in hepatitis B and C infections, and decreasing immune responses to
vaccines for hepatitis B and possibly measles. The studies that we analyzed also suggested
that schistosome infection may protect the host against poor clinical outcomes from some
viral infections including Human T-cell Lymphotropic Virus-Type 1, respiratory viruses,
and chronic HIV. We discuss how these findings might be interpreted, and the additional
research needed, in order to improve anti-viral vaccination strategies and control of viral
infections globally.
Introduction
Viral infections caused over 3 million deaths worldwide in 2017 [1,2], and will likely contribute
over 1 million more in 2020 due to COVID-19 [3]. Global viral outbreaks including COVID-
19, HIV, and influenza illustrate the critical need to understand how and why the same virus
may cause mild disease in some hosts, yet trigger severe disease and death in others.
Helminth infections affect over 2 billion people worldwide and disproportionately infect
the world’s poor [4]. A growing body of literature suggests that helminth infections, particu-
larly schistosomes, affect both host susceptibility to viruses and the severity of viral illness via
their impact on the host immune system. While previous reviews have investigated effects of
schistosome co-infection on HIV [5–8] or hepatitis viruses [9–11], a more comprehensive
analysis of the impact of schistosome infection on viral acquisition, virulence, and prevention
has not been undertaken.
Schistosomes infect at least 229 million people globally and are treatable with praziquantel
[12]. Parasitic worms lay eggs that damage tissue of the gastrointestinal (S.mansoni, S. japoni-
cum) and genitourinary (S. haematobium) tracts, causing ~1.5 million disability-adjusted life
years (DALYs) lost annually [13]. If schistosome infection additionally exacerbates viral sus-
ceptibility or virulence, the burden of DALYs lost may be higher. Conversely, if schistosomes
benefit the host in some instances, this might hold potential for new therapeutic and preven-
tion strategies against viral infections.
In this review, we systematically examine the effects of schistosome infection on viral infec-
tions. We hypothesized that this broader investigation would provide insights to guide future
research, with potential to impact the public health effects of viruses. We focused on how schisto-
some co-infection impacts specific viral infections by examining: host anti-viral immune
responses, prevalence and incidence of the viral infection, virulence, and anti-viral vaccination.
Methods
This systematic review utilized the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines [14] and was registered prospectively in PROSPERO
(CRD42019129533).
Search strategy
Comprehensive literature searches were developed and performed by a medical librarian
[KM]. The initial search was performed March 28, 2019 via OVID MEDLINE ALL
(1946-March 27, 2019). The Cochrane Library (Cochrane Database of Systematic Reviews,
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Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology Register,
Technology Assessments (HTA)), LILACS (Latin American and Caribbean Health Sciences
Literature), and OVID EMBASE (1974-March 28, 2019) were searched on March 29, 2019;
Scopus (Elsevier) on April 1, 2019. Follow-up searches were performed on December 9, 2019.
Search terms included all subject headings and/or keywords associated with our research ques-
tion, clustered as:
1. Parasite or proxy for parasitic infection (e.g. Schistosoma, Schistosomiasis);
2. Virus or vaccine-related headings (e.g. Virus, Virology, Vaccine, Vaccination);
3. Immune response or physiologic state indicative of host immune response (e.g. Immuno-
modulation, Lymphocyte Activation, Biomarkers, Disease Susceptibility, Cellular Immu-
nity, Coinfection, HIV, T-Lymphocytes).
Boolean operators ‘OR’ and ‘AND’ were used as appropriate. Grey literature and bibliogra-
phies of included articles were also searched; see full search strategy in the Supplementary
Appendix (S1 Text). Publication date or article-type restrictions were not imposed.
Study selection
After excluding duplicates, two investigators [BB, KK] independently screened titles and
abstracts using Covidence, a systematic review tool. Discrepancies were resolved indepen-
dently by a third investigator [JD]. We included studies describing the effects of schistosomes
on viral infections, anti-viral immunity, or anti-viral vaccinations and defined virulence as
severity of clinical disease in co-infected subjects [15]. This definition of virulence aligned with
the definitions used in included manuscripts. Pre-defined exclusion criteria included: popula-
tions with and without viruses rather than with and without schistosome infection, focus on
non-viruses, not available in English, and study design of case study or case review. We pre-
specified that studies must test for active schistosome infection by microscopy or antigen and
that we would exclude studies that relied on schistosome antibody testing due to antibodies
remaining positive after clearance of infection (see S2 Text for full decision rules for data selec-
tion and extraction).
Full-text review followed the initial title and abstract screening phase, with data extracted
into Microsoft Excel. Following Cochrane Collaboration guidance, included articles were eval-
uated for credibility, transferability, dependability, and confirmability [16] using Critical
Appraisal Skills Programme checklists [17]. Discrepant analyses of study quality were resolved
by discussion and author consensus. Due to heterogeneity of study designs, animal and
human studies, and different viral infections, a meta-analysis was not possible.
Results
Titles and abstracts of 4,731 studies were screened, and 313 full-text papers were assessed for
inclusion. 14 additional records were identified from the grey literature, expert recommenda-
tions, and screening bibliographies. Excluded studies are listed in S1 Table. A total of 103 stud-
ies were included (Fig 1 and S2 Table).
We identified studies examining effects of schistosome coinfection on 7 categories of
viruses: hepatotropic viruses such as Hepatitis B and C (HBV, HCV), Human Immunodefi-
ciency Virus (HIV), Human papillomavirus (HPV), Human T-cell leukemia virus type 1
(HTLV-1), Kaposi’s sarcoma-associated herpesvirus (KSHV), respiratory viruses (influenza,
murine herpesviruses), and rubeola virus vaccination.
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Fig 1. PRISMA flow diagram showing records identified by searching, screened, assessed for eligibility, and included in the systematic review.
https://doi.org/10.1371/journal.ppat.1009555.g001
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The schistosome-infected host exhibits a dynamic immune response to schistosome infec-
tion that is initially dominated by Th1 with some contributions from Th2, and then shifts over
time towards Th2 and T regulatory (T reg) dominance during chronic infection [18,19]. The
concomitant decrease in Th1 cytokines during this chronic phase underlies the hypothesis that
the schistosome-infected host may develop impaired Th1 anti-viral and cytotoxic immune
function. Most studies in this review examined immune effects of schistosome-virus coinfec-
tion during chronic schistosome infection. We examine each category of virus separately, first
reviewing reported immune effects of schistosome-virus coinfection and then examining
effects on viral prevalence/incidence, virulence, and vaccination for each virus.
Hepatitis B and C viruses
Effects of schistosome infection on host immune response to HCV. In total, 15 studies
described effects of schistosome infection on immune response to HCV and none focused on
HBV (Table 1).
Six studies investigated circulating T cells in HCV-schistosome coinfected individuals compared
to those with HCV alone [20–24]. In one of these, S.mansoni-infected patients who acutely acquired
HCV developed a Th2 and T reg-dominant response and 17/17 failed to clear HCV, while those
without S.mansoni infection developed a Th1-dominant response and 5/15 cleared HCV infection
[20]. Both this study and another documented lower HCV-specific CD4+ proliferative responses to
HCV antigens in those with HCV-schistosome coinfection [20,21]. Two others reported no differ-
ences in CD4+ or CD8+ T cells, [22] or in CD4+ or CD8+ granzyme B+ effector T cells, although
granzyme B+ effector T regs were increased in coinfection [23]. The fifth study reported fewer late
differentiated HCV-specific memory T cells in coinfected individuals compared to those with HCV
alone [24]. In the sixth study, S.mansoni-coinfected persons exhibited less frequent and smaller
intrahepatic HCV-specific CD4+ Th1 responses than those with HCV mono-infection, and biopsy-
confirmed liver fibrosis was inversely correlated with the Th1 immune response [25].
Five studies evaluated host cytokine responses to HCV in schistosome-HCV coinfection ver-
sus HCV-monoinfection [23,26–29]. Two of these reported higher serum IL-4 and IL-10 and
lower interferon-gamma (IFN-γ) levels in coinfected individuals [26,27], although two others
did not [23,28]. Another reported higher IL-10 and lower IFN-γ in response to generic mitogen
stimulation although not to HCV-specific stimulation [29]. Together, these studies generally
support impaired Th1 anti-viral immunity in patients with schistosome-HCV coinfection.
Two studies investigated the role of HCV-schistosome coinfection in viral propagation in
humans [30,31] and one investigated an analogous virus in mice [32]. In humans, HCV-
infected blood samples cultured with S.mansoni [30] or S. haematobium [31] egg antigens had
increased intracellular HCV replication and earlier detectable HCV RNA than HCV-infected
blood samples cultured without schistosome egg antigens. Concordantly, the study in mice
reported increased intrahepatic viral replication and reduced type 1 IFN production [32].
These findings are in agreement with data from some [23–25,28], but not all [27,29], studies
that reported higher HCV RNA viral loads in patients with schistosome-HCV coinfection.
Two additional studies reported that S.mansoni-HCV coinfected patients had poorer
response to interferon therapy than HCV-monoinfected patients, marked by more frequent
relapses and poorer hepatic histologic improvement six months after therapy [33,34]. Studies
assessing effects of schistosome infection with newer, direct-acting antivirals for HCV have
not been performed. Together, this body of data consistently suggests impaired antiviral
immune responses and poorer viral control in HCV-S.mansoni coinfection than HCV alone.
Schistosomes and prevalence of HBV and HCV. Studies on associations between schis-
tosomes and HBV or HCV prevalence reported up to 2015 were previously summarized by
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Abruzzi and colleagues [9] and therefore are not discussed in detail here. Briefly, schistosome
infection is not associated with increased prevalence of HBV or HCV, aside from one study in
Egypt where parenteral anti-schistosome treatment likely caused iatrogenic hepatitis infec-
tions. No additional studies of HBV or HCV prevalence or incidence that met inclusion crite-
ria have been published since the 2015 review.
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Schistosomes and virulence of HBV and HCV. Abruzzi and colleagues have meticu-
lously summarized effects of schistosome-hepatitis virus coinfection on liver pathology [9],
including several of the HCV immunology studies discussed above that also addressed viru-
lence [20,21,25,27]. They concluded that studies in patients with schistosome-HCV coinfec-
tion indicate that schistosome-hepatitis coinfections have synergistic effects on liver disease.
This was demonstrated by increased transaminases, cirrhosis, and/or portal hypertension in
coinfected patients versus those with schistosomes or HCV alone. An additional HCV study
published after the review also supports this finding [35].
Four studies in the Abruzzi review similarly reported that HBV-schistosome coinfected peo-
ple had prolonged HbSAg antigenemia and greater liver fibrosis and splenomegaly compared to
those with HBV alone. In a mouse model of HBV not included in the review, S.mansoni infec-
tion similarly promoted viral persistence, although liver pathology was decreased in coinfected
compared to HBV-monoinfected mice during the T regulatory-dominant chronic phase of S.
mansoni infection [36]. Interestingly, coinfected mice also cleared acute HBV infection more
quickly during both the Th1-dominant acute phase of schistosome infection and the chronic T
regulatory dominant phase [36]. These studies demonstrate the important role that timing of
infections may have on viral virulence and the need for human data to clarify these findings.
Two small studies examined effects of praziquantel treatment on HBV disease course. In
ten S.mansoni-HBV co-infected individuals, HBsAg remained positive in the four individuals
with persistent S.mansoni six months post-treatment, versus in only one of six who were para-
sitologically cured [37]. The other study reported that praziquantel treatment of HBV-S.man-
soni coinfected individuals led to clearance of HbSAg in 20% and normalization of liver
transaminases in ~15% after 6 months, while those with HBV alone who were followed for 6
months had no clearance of HbSAg and ~10% developed abnormal transaminases [38].
Schistosomes and HBV vaccination. Eight studies investigated hepatitis B vaccine immu-
nogenicity with and without schistosome coinfection (Table 2). Mice with chronic S. japoni-
cum had significantly attenuated anti-hepatitis B surface (HBs) antibody response to hepatitis
B vaccine, and anti-HBs antibody titers increased after praziquantel treatment [39]. Two stud-
ies reported lower post-vaccine anti-HBs titers in S.mansoni-infected children [40] and adults
[41]. Titers in S.mansoni-infected adults were lower two weeks after the second hepatitis B
vaccine dose, with a trend towards remaining lower after three doses [41]. Another study
involving 504 children found no impact of S.mansoni infection on anti-HBs antibody titers
when children were given praziquantel treatment and vaccinated concurrently [42]. These
data suggest that hepatitis B vaccine response may be compromised by schistosome infection
and improved after treatment. Notably, four studies reported that maternal schistosome infec-
tion does not impair neonatal response to hepatitis B vaccine [43–46].
Collectively, these data demonstrate that schistosome infection is associated with impaired
anti-viral immune responses and subsequent increased viral replication and liver damage. This
has been particularly well studied in adults with S.mansoni and HCV; very little is known in
children who have acquired HBV perinatally. Schistosome infection does appear to depress
the humoral HBV vaccine response in children. Importantly, praziquantel may aid viral con-
trol, decrease liver pathology, and improve HBV vaccine response and could be an effective
means to decrease global burden of these viral infections in schistosomiasis endemic regions.
HIV
Effects of schistosome infection on host immune response to HIV. Three studies inves-
tigated the mucosal anti-HIV immune defense in HIV-uninfected women (Table 3). One
study documented associations of S. haematobium infection with higher frequencies of CD14+
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and CD4+ cells expressing the HIV coreceptor CCR5 in the genital tract and systemic circula-
tion, which decreased after praziquantel treatment [47]. An in-vitro study found that HIV
viral entry into cervical and systemic CD4+ cells was higher in S.mansoni-infected women and
decreased after praziquantel treatment [48]. Treatment of S.mansoni infection also partially
normalized dysregulated anti-viral interferon signaling [48]. This corresponds with observed
lower levels of anti-viral cytokine interleukin-15 in cervicovaginal lavages of S. haematobium-
infected women [49]. By contrast, immune cell populations were not altered in the foreskins of
men with S.mansoni infection [50]. Taken together, these consistently report that schisto-
some-infected women have genital mucosal alterations in immune cell populations, anti-viral
signaling, and HIV viral entry. Together with physical breaches of the mucosal barrier by
schistosome eggs, these may contribute to increased susceptibility to mucosal HIV acquisition
in women.
Five additional human studies examined host systemic immunity in HIV-schistosome coin-
fected patients, and all reported increased Th2 or Treg responses in those with coinfection ver-
sus those with HIV alone [50–54]. HIV-schistosome coinfected men had higher densities of
HIV co-receptors CXCR4 and CCR5 on the surface of CD4+ T cells, which were upregulated
by Th2/Treg cytokines IL-4 and IL-10 [51]. Higher systemic frequencies of HIV-susceptible
Th1, Th17, and Th22 CD4+ T cell subsets were also observed in HIV-uninfected men with S.
mansoni [50]. Stimulation of PBMCs with HIV-1 Gag peptides yielded decreased Gag-specific
CD8+ cytolytic T-cell responses and increased Gag-specific IL-10-positive CD8+ T-cell
responses in HIV-S.mansoni coinfected compared to HIV-monoinfected individuals, suggest-
ing dysregulated cellular immunity to HIV [52]. These five studies thus demonstrate
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schistosome-associated alterations in host systemic immunity that could confer increased sus-
ceptibility to HIV.
Notably, some upregulations in pro-inflammatory markers IL-8, TNF receptor sTNF-rII,
and TNF-α have been documented in schistosome-HIV coinfection, possibly consistent with
heightened Th1 response following recent HIV acquisition [53,54]. However, overall, these
human studies report that schistosome coinfection downregulates Th1 and cytotoxic immune
responses and upregulates Th2 and Treg responses in HIV-infected individuals, and that treat-
ing the schistosome infection modulates these differences.
Eight animal studies reported decreased Th1 and increased Th2/T reg responses to HIV
during schistosome infection [55–62]. In the first, splenocytes from S.mansoni-infected mice
stimulated with HIV vaccine candidates produced less IFN-γ and IL-2 than S.mansoni-unin-
fected, vaccinated mice, and partial restoration was observed after anti-schistosome treatment
[55]. In two other studies, mice with vaccinia-S.mansoni coinfection produced minimal IFN-γ
and IL-2 in response to viral challenge with recombinant vaccinia virus expressing the HIV
glycoprotein gp160, and exhibited delayed viral clearance, compared to mice with vaccinia
alone [56,57]. Longitudinal mouse studies documented delayed viral clearance only after the
onset of worm egg-laying, correlating with decreasing IFN-γ and IL-2, impaired viral-specific
cytotoxic CD8+ T-cell responses [58], and increased IL-4 [59]. The Th2 predominance after
egg-laying further links the impaired anti-viral response during schistosome infection to dwin-
dling Th1 immune responses at the time of worm maturation and oviposition [63]. Elevated
Th2/T reg cytokines and decreased IFN-γ have also been reported in macaques with sHIV-
schistosome coinfection and have been linked to increased sHIV replication in macrophages
[60–62]. Together, these animal studies support the human findings of Th2 predominance and
potentially impaired anti-HIV immunity during chronic schistosome infection.
Finally, an in vitro study documented increased resistance to trans-infection in HIV-sus-
ceptible human dendritic cells that matured while exposed to schistosome egg antigens in a
Th2-predominant environment compared to cells that matured in a Th1 environment [64].
This suggests that during schistosome-HIV coinfection, HIV may spread less readily from
cell-to-cell via trans-infection than during HIV mono-infection, indicating a potential means
by which schistosome coinfection, perhaps unexpectedly, could slow viral replication and dis-
ease progression.
Schistosomes and prevalence and incidence of HIV. Cross-sectional studies investigat-
ing HIV prevalence in schistosome-infected and -uninfected individuals have been inconclu-
sive (Table 4). Four studies reported higher prevalence of HIV in schistosome-infected versus
uninfected women [65–68], of which three focused on S. haematobium infection. Five others,
conducted in S.mansoni-hyperendemic regions or in men only, found no difference by schis-
tosome status [69–73], although at least one was under-powered.
Five studies investigated effects of schistosome infection on HIV incidence. In a nested
case-control study in Uganda, investigators found no increased incidence of HIV in S.man-
soni-infected people, although the odds of incident HIV was eight-fold higher in those who
had not received anti-schistosome treatment in the past two years [74]. Increased incidence of
HIV was similarly not observed in serodiscordant couples and sex workers in Uganda and
Kenya who had either S. haematobium or S.mansoni infection [75]. In a cohort in Tanzania,
persons who had S. haematobium eggs in urine at any point during the study did not have
increased HIV incidence [76]. In contrast, a nested case-control study in Tanzania reported
increased odds of HIV acquisition (OR = 2.8 [95% confidence interval, 1.2–6.6]) in schisto-
some-infected women but not men [77]. One additional study reported no increased mother-
to-child HIV transmission from schistosome-infected mothers, although infection with any
helminth (including schistosomes) strongly increased odds of HIV transmission suggesting
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the study may have been underpowered to examine individual helminths [78]. Additional
challenges with this body of evidence include lack of control for confounders including sexu-
ally-transmitted infections in high-risk cohorts [75], unclear timing of anti-schistosome
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Some studies suggest









Sh/Sm prevalence was 27% among HIV-
seroconverters and 25% among controls
Trend toward increased risk for Sh in
women (36% versus 25%).
Kroidl 2016
[76]
Human 1055 51% F 15.4 Tanzania Sh HIV incidence per 100 person-years: 1.3
among Sh 1.2 among uninfected
Downs 2017
[77]
Human 338 61% F Not reported Tanzania Sh and
Sm
Women: Sh/Sm prevalence was 43%
among HIV-seroconverters and 30%
among controls�
Men: 29% among HIV-seroconverters
and 38% among controls
Galla-gher
2005 [78]
Human 936 100% F Not reported Kenya Sh Sh prevalence was 17% among mothers
who transmitted HIV to children and 9%
among mothers who did not [85% versus
40% for any helminth]�
Chenine
2008 [79]
Animal 17 100% F N/A N/A Sm 17-fold lower sHIV viral dose needed to





Animal 16 100% F N/A N/A Sm No difference in sHIV dose needed to
achieve intravenous infection
† Sh = S. haematobium; Sm = S.mansoni; Sj = S. japonicum
� Difference was statistically significant.
# Approximate calculation; data was incomplete to determine precise weighted mean.
https://doi.org/10.1371/journal.ppat.1009555.t004
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treatment in relation to HIV acquisition [76], and use of assays unable to differentiate between
schistosome species [77].
Studies in macaques more clearly support increased HIV susceptibility during schistosome
infection. Investigators reported that S.mansoni-infected macaques, when rectally inoculated
with increasing doses of simian HIV (sHIV), became infected at viral doses 17-fold lower than
schistosome-uninfected macaques [79]. The same investigators found no difference in sHIV
dose needed to achieve infection when schistosome-infected and uninfected macaques were
infected intravenously, suggesting that the sHIV susceptibility is mediated by mucosal effects
of S.mansoni [80]. Because macaques received rectal sHIV inoculation, S.mansoni in these
studies may mimic the effects of S. haematobium infection on vaginal HIV exposure in
humans. Although parasite eggs can be found in the genital tract in both S. haematobium and
S.mansoni infections, they are more highly concentrated and associated with greater genital
tract pathology in S. haematobium [81–84].
Overall, this body of evidence is inconclusive but suggests that schistosome infection may
increase the risk for HIV acquisition in women, with a stronger signal toward increased risk
with S. haematobium. The evidence for S.mansoni is mixed and an association with HIV, if
present, may be lower in magnitude. This is corroborated by a third, larger nested case-control
study, not eligible for inclusion in the review due to its use of antibody testing, which reported
a moderately increased hazard of HIV acquisition in women with anti-S. haematobium anti-
bodies and a smaller increased hazard for women with anti-S.mansoni antibodies that did not
reach significance (hazard ratios = 1.44 [1.05–1.96] and 1.30 [0.91–1.87], respectively) [85].
Interestingly, that case-control study also indicated that the presence of anti-schistosome
antibodies was associated with increased transmission of HIV from HIV-infected men and
women to their sexual partners, as well as with increased hazard of death in HIV-infected
women [85]. Men with S. haematobium infection have also been reported to have an increased
concentration of leukocytes and eosinophils in semen, cell types that are permissive to HIV
replication and may facilitate onward HIV transmission from men with HIV-S. haematobium
coinfection to their sexual partners [86]. Further supporting this possibility, a small study of 6
HIV-S. haematobium coinfected men who were not on ART and were treated with praziquan-
tel reported a decrease in HIV-1 RNA viral load in semen from baseline to 10 weeks post-treat-
ment, though this did not reach significance [87].
Schistosomes and HIV virulence. One study reported that S.mansoni-HIV coinfection
was associated with elevated liver transaminases after controlling for other known causes of
transaminitis (HBV, HCV, alcohol, medications) in patients on ART [88]. This suggests that S.
mansoni infection could potentiate direct hepatotoxicity of HIV on hepatocytes [89].
Thirteen studies examined effects of HIV-schistosome coinfection on CD4+ T cell counts
(Table 5). Seven found no relationship [54,72,90–94], one reported higher CD4+ counts [95],
and one reported lower increase in CD4+ counts following ART initiation in coinfected
patients [96]. Four other studies found no difference in CD4+ counts before and 12 weeks after
praziquantel treatment [95,97,98] or in those given praziquantel quarterly versus annually
[99]. Another study reported that individuals successfully treated for schistosome infection
had lower CD4+ counts after six months than those still infected [100]. Taken together, these
studies indicate that schistosome infection does not consistently affect CD4+ count, and that
treatment of schistosome infection seems not to increase, and could possibly decrease, CD4+
counts.
Seven studies examined schistosome infection and HIV-1 viral load. In adults who had
recently acquired HIV, median viral load was higher in those with HIV-schistosome coinfec-
tion than with HIV alone in one study [77] but lower in a combined analysis of four cohort
studies in higher-risk populations [101]. Cervical HIV-1 viral loads were also unexpectedly
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lower in S. haematobium-coinfected patients [101]. In four studies among patients with
advanced HIV infection, schistosome-HIV coinfected individuals had lower viral loads in one
[92]. higher viral loads in one [98], and no significant differences in two [90,95]. Another
study reported no difference in viral loads by schistosome status among patients failing first-
line ART [102]. These discrepant results suggest a complex relationship between schistosome
infection and HIV-1 viral load that may be influenced by duration of HIV infection. Macaques
with S.mansoni infection also had higher HIV-1 viral loads shortly after mucosal HIV acquisi-
tion, which declined over time [79], though macaques naturally clear S.mansoni infection
after several months and this precludes definite conclusions [60].
Examination of the effects of praziquantel treatment on viral load provides additional
insight. In six studies of viral load in HIV-schistosome coinfected individuals within six
months of praziquantel treatment, two reported no difference before and after treatment
Table 5. Effects of Schistosome-HIV Coinfection on CD4+ T Cell Counts, HIV-1 RNA Viral Load, and HIV Disease Progression.
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Also, viral loads increased pre-
treatment those whose
praziquantel was delayed
Brown 2005 [100] Abaasa 2018 [99]









Slower HIV Disease Progression in those with Chronic HIV-Schistosome Coinfection
Colombe 2018 [93]
Patients not yet on ART
Outcome: CD4+ count< 350 cells/μL or death
Hazard ratio = 0.31 [0.12–0.84]
Abaasa 2018 [99]
Patients not yet eligible for ART
Outcome: progression to AIDS




Outcome: death or loss-to-
follow-up
Hazard ratio = 0.58 [0.32–
1.05]
https://doi.org/10.1371/journal.ppat.1009555.t005
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[90,98]. One small randomized trial reported higher viral loads in HIV-schistosome coinfected
persons randomized to receive delayed treatment after three months than in persons who
received praziquantel at baseline [103]. Two other studies reported increases in viral loads 4–5
weeks after treatment, which were not sustained when re-measured 4–5 months after treat-
ment [95,100]. The transient increase in viral load was especially prominent in patients with
high-intensity schistosome infection at baseline [100]. Together, these consistently report
increased HIV-1 viral load shortly after praziquantel treatment, which decreased within three
months. Notably, these studies neither categorized people by treatment success or failure, nor
controlled for other possible causes of viral load elevations.
In contrast, two studies examined effects of praziquantel treatment over periods longer
than six months and assessed for schistosome eradication. One pre-ART study reported
increased viral load after effective treatment, particularly six or more months post-treatment
[104]. In the other study, schistosome-infected persons not yet eligible for ART who received
quarterly praziquantel treatment also tended towards higher viral loads, as compared to con-
trols who received praziquantel once and among whom 73% remained infected one year post-
treatment (mean viral load ratio 1.88 [0.78, 4.53] p = 0.16) [99]. Therefore, these two studies
suggest, rather unexpectedly, that long-term successful treatment of schistosome coinfection
could increase HIV-1 viral load.
Consistent with these findings, three longitudinal studies have suggested slower HIV dis-
ease progression in those with chronic HIV-schistosome coinfection, versus those with HIV
infection alone—results that contradicted investigators’ original hypotheses. In the first study,
people with schistosome coinfection not yet on ART had a lower hazard ratio of developing
CD4+ counts <350 cells/μL or death (HR = 0.31 [0.12–0.84]) [93]. The study of quarterly pra-
ziquantel treatment described above also reported a trend toward increased risk of progression
to AIDS in the intensively-treated, ART-naïve group (log-rank chi-square 2.08, p = 0.15) [99].
A third study reported a hazard ratio of 0.58 [0.32–1.05] for death or loss to follow-up in those
with HIV-schistosome coinfection starting ART, almost reaching significance [105].
Differences in results reported in these studies highlight the complexity of the relationship
between HIV-1 viral load and schistosome infection, which may vary by schistosome species,
other coinfections, and parasite and/or viral dynamics. One possible hypothesis to harmonize
these studies is that schistosome and HIV infections could interact differently over time, with
HIV-1 viral load set-points elevated shortly after HIV acquisition in some groups of people
with schistosome coinfection, and later becoming lower in coinfected people as HIV becomes
chronic. Taken together, these data raise the possibility that, in people with chronic HIV-schis-
tosome co-infection, viral loads may be lower and disease progression slower than in chronic
HIV alone.
Schistosomes and HIV vaccination. Three murine studies reported lower magnitude of
HIV-specific CD8+ T-cell responses to HIV vaccines in schistosome-infected than uninfected
mice (Table 6) [55,106,107]. In one of these, mice given praziquantel two weeks before vacci-
nation still had lower titers of gp140-specific IgG antibodies and only partial restoration of
CD4+ and CD8+ T-cell responses 12 days after vaccination [55]. Further, the presence of schis-
tosome eggs in tissue, even in the absence of active worm infection, attenuated anti-gp140 anti-
body responses [55]. Another study reported that S.mansoni infection attenuated HIV-
specific CD8+ IFN-γ secretion [106]. Praziquantel treatment four weeks before vaccination
caused partial restoration of this CD8+ response, and treatment eight weeks before vaccination
completely restored this response [107]. These studies collectively demonstrate that schisto-
some infection could decrease CD8+ T-cell responses to an HIV vaccine, and that restoration
of CD8+ responses occurs at least eight weeks after treatment, the approximate time over
which the burden of eggs trapped in tissue decreases [108].
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Herpesviruses in mice and humans
Herpesviruses, which cause lifelong infection marked by periods of latency and reactivation,
may offer important insights into interactions between schistosomes and viruses. A study in
mice with chronic latent murine γ-herpesvirus that were infected with S.mansoni developed
systemic herpesvirus reactivation with concomitant increases in IL-4 and decreased IFN-γ
compared to herpesvirus mono-infected mice (Table 7) [109].
In China, men with S. japonicum infection had higher KSHV seroprevalence compared to
men without S. japonicum, although no difference was observed in women [110]. Similarly, no
difference in KSHV seroprevalence was observed in pregnant women in Uganda based on S.
mansoni status [111]. In contrast, in Ugandan fishing communities, seroprevalence of KSHV
was 89% in those with S.mansoni infection versus 77% in those without, and odds of KSHV
remained significant after adjusting for sex, age, and other parasitic infections [112]. In addi-
tion, elevated anti-K8.1 antibodies in S.mansoni infection suggested increased KSHV reactiva-
tion [112]. These studies, supported by mouse models discussed previously [109], suggest that
Table 6. Effects of Schistosoma mansoni Infection on Response to HIV Vaccine in Mice.
Study Study Design Time Elapsed Between
Vaccine and
Assessment
Vaccine Response in Schistosome
Infected




Mice with and without Sm were given
candidate HIV vaccines





#HIV-specific splenocyte IFN-γ and IL-
2 secretion
Partial restoration of IFN-γ and IL-2
after PZQ
# gp-140 IgG antibody production in Sm
Impaired HIV-specific cellular immune
response to HIV vaccine
Cellular immune response was restored
completely when PZQ treatment was




Mice with and without Sm were given
candidate HIV vaccines
2 weeks #HIV-specific IFN-γ secretion by CD8+
T cells in Sm
Da’dara 2010
[107]
Mice with Sm, mice with prior Sm
who were treated, and uninfected
mice were given candidate HIV
vaccines
2 weeks post-vaccine
(vaccinated 4 or 8 weeks
after PZQ)
"HIV-specific IFN-γ secretion by CD8+
T cells after PZQ (completely restored
when vaccinated 8 weeks after PZQ)
�PZQ = praziquantel
https://doi.org/10.1371/journal.ppat.1009555.t006
Table 7. Effects of Schistosome Infection on the Host Immune Response to Herpesviruses, and on Prevalence of Kaposi’s Sarcoma-Associated Herpesvirus.






Country Species† Differences in Schistosome
Infected Compared to Uninfected












Reactivation was dependent on
IL-4 and STAT-6
Increased Th2 cyto-kines were
associated with systemic viral
reactivation.
Increased KSHV sero-prevalence in
Sm, with evidence stronger for men.
Fu 2012 [110] Human, KSHV 105 47% F, Age range
not reported
China Sj KSHV prevalence:
8.4% among Sj
6.6% among uninfected
(men: 8.4% versus 2.2%)�
Wakeham
2011 [111]
Human, KSHV 1915 100% F, median
age 23





Human, KSHV 1137 44% F, median
age 25
Uganda Sm KSHV prevalence: 89% among
Sm 77% among uninfected�
Odds increased after controlling
for sex�
†Sm = S.mansoni; Sh = S. haematobium; Sj = S. japonicum; Hp = Heligmosomoides polygyrus
�Statistically significant
https://doi.org/10.1371/journal.ppat.1009555.t007
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KSHV is an additional virus for which schistosome infection may impair host anti-viral
defense and subsequent control, with stronger evidence for this effect in men than in women.
Respiratory viruses
Effects of schistosome infection on host immune response to respiratory viruses. Five
studies have investigated immune effects of S.mansoni infection on respiratory viruses in mice
(Table 8). In the first study, mice with acute respiratory herpesvirus-S.mansoni coinfection
had increased IL-4 and expanded CD8+ T-cell viral-specific effector responses in the lung,
leading to enhanced control of the respiratory virus [113]. This suggests that schistosome-
induced Th2 predominance, demonstrated here by increased IL-4, may be beneficial for viral
control in the lung.
A similar beneficial anti-viral effect in the lung has been observed in mice coinfected with
S.mansoni plus influenza A. Mice with S.mansoni infection that were challenged with influ-
enza A virus had decreased mortality, decreased weight loss, decreased alveolar inflammation,
lower expression of pro-inflammatory cytokines IL-6 and TNF-α, and greater lung epithelial
regeneration than mice without S.mansoni [114–116]. Comparable beneficial effects have
been observed in mice with S.mansoni and pneumonia virus [117] and in studies of other hel-
minths [118]. Proposed mechanisms for protection include goblet cell hyperplasia, excessive
mucus secretion, and alterations in interferon levels. These intriguing data may be attributable
to the unique environment of the lung compared to the rest of the body. Together with the
studies of schistosome infection during chronic HIV, these mouse respiratory virus data exem-
plify another scenario in which schistosome-viral coinfection may be surprisingly beneficial
compared to viral infection alone.
Table 8. Effects of Schistosome Infection on the Host Immune Response to Respiratory Viruses in Mice.
Study Virus Sex (%
Female)
Species† Differences in Schistosome Infected
Compared to Uninfected





100% F Sm In lung:
" IL-4
" CD8+ T-cell viral-specific effector
responses
# virus titers
Increased Th2 responses and decreased Th1 responses
were associated with better viral control in the lung.
Danz 2016
[114]
Influenza A 100% F Sm #mortality and morbidity
# influenza-specific IFN-γ secretion
by mediastinal CD8+ T cells






Sm # weight loss and lung injury
" dendritic cells and alternatively
activated macrophages in lungs






" influenza-specific IgM & IgG









Sm #mortality and weight loss
"mucus production and goblet cell
hyperplasia in lungs
# lung viral burden
†Sm = S.mansoni; Sh = S. haematobium; Sj = S. japonicum; Hp = Heligmosomoides polygyrus
�Statistically significant
https://doi.org/10.1371/journal.ppat.1009555.t008
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Human papillomavirus
Schistosomes and prevalence of HPV. Two small studies suggested possible interactions
between S. haematobium and HPV. In 37 women followed for 5 years, S. haematobium was
associated with development of high-grade squamous intraepithelial neoplasia but not with
high-risk HPV persistence (Table 9) [119]. Genital HPV DNA was also associated with
reported or confirmed S. haematobium in Tanzania, but only 6 women had confirmed schisto-
some infection [120]. Therefore, despite both pathogens affecting the genital mucosa, interac-
tions between S. haematobium and HPV remain poorly understood.
Schistosomes and HPV vaccination. Two studies have investigated the effect of schisto-
some infection on HPV vaccination. A small number of S.mansoni-infected baboons had
lower HPV IgG antibody titers than baboons without schistosome infection, though prazi-
quantel treatment prior to vaccination eliminated these differences [121]. However, a large
study reported no difference in anti-HPV antibody titers seven and 12 months after HPV vac-
cination in 298 girls and women aged 10–25 with versus without S.mansoni infection [122].
Importantly, diagnosis of schistosomes by egg excretion, which is poorly sensitive in women
[123], could have led to misclassification of infected women. Additional studies to understand
schistosome-HPV interactions should be prioritized.
Human T-cell leukemia virus type 1 (HTLV-1)
Effects of schistosome infection on host immune response to HTLV-1. Three studies
examined effects of S.mansoni coinfection on Th1 proinflammatory responses in HTLV-1,
which are associated with development of tropical spastic paralysis [124]. In two studies, the
addition of S.mansoni antigens to PBMC cultures from HTLV-1-infected adults caused
increased IL-10 and decreased IFN-γ and CXCL9, important for Th1 cell recruitment
[125,126]. Another reported decreased IFN-γ and increased IL-10 in unstimulated PBMC cul-
tures of adults with HTLV-1-helminth co-infection versus with HTLV-1 alone [127], as well as
decreased HTLV-1 proviral load in PBMCs of those with coinfection [124]. These data fit with
one study’s clinical documentation of schistosome or strongyloides infections seven-fold more
frequently in HTLV-1 disease carriers than in HTLV-1 infected persons who developed tropi-
cal spastic paralysis [124], suggesting that decreased Th1 and increased T regulatory could pre-
vent the development of inflammatory paralysis. In this instance, HTLV-1 could be another
viral infection that is positively impacted by schistosome coinfection and confirmatory studies
are needed.
Rubeola virus (measles)
Schistosomes and measles vaccination. Five studies examined the effect of S.mansoni on
measles vaccine response. In the first, preschool children with S.mansoni infection who
received catch-up measles vaccination achieved lower anti-measles IgG titers. Children treated
with praziquantel treatment before or at the time of catch-up measles immunization developed
higher IgG titers than children treated after immunization, and children who remained schis-
tosome-infected 24 weeks post-vaccination had lower IgG titers than those cured [128]. Lower
anti-measles IgG titers were similarly documented in S.mansoni-infected schoolchildren
[129], though a second study showed robust Th1 and pro-inflammatory post-vaccination cyto-
kine responses to measles antigens [130]. Another study reported that two-year-old children
born to mothers with S.mansoni had lower anti-measles IgG titers than those born to unin-
fected mothers [131], although no titer differences were observed in one-year-olds [132] and
neither study determined schistosome infection status of the children. In HIV-infected antire-
troviral therapy (ART)-naïve adults, anti-measles IgG titers were similar regardless of
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Human 37 100% F Range, 20–55 Zimbab-we Sh 7 women developed HGSIL
and 6 had Sh�
No effect on HPV persistence
(29% versus 19%)
Possible increases in HPV




Human 218 100% F Median,28.4 Tanzaniaand
Germany
Sh Borderline "HPV prevalence







Sub-adult NA Sm #HPV-specific IgG after
vaccination in Sh
IgG restored in baboons given
PZQ before vaccine
Discrepant data; large human
study suggests no effect
Brown 2014
[122]





Human 26 42% F 48 Brazil Sm # IFN-γ and " IL-10 after
schistosome antigen
stimulation
Decreased Th1 cytokines and
HTLV-1 viral load in vitro, which
may contribute to observed lower
rates of tropical spastic paralysisLima 2017
[126]















Brazil Sm # IFN-γ and " IL-10
# frequency of CD4+ and CD8
�
IFN-γ secreting cells
#HTLV-1 proviral DNA load
in PBMCs




Human 239 53% F 3.9 years Uganda Sm # anti-measles IgG in Sm at
one week; lower IgG trend at 6
months
# % with protective antibody
levels in Sm
# anti-measles IgG after PZQ
Active schisto-some infection
during measles vaccine may
impair anti-measles antibody
response.
Maternal Sm infection did not
consistently impact children’s
measles vaccine response.







Range, 5–18 Came-roon Sh, Sm # anti-measles IgG in Sm but






Range, 7–16 Phili-ppines Not
listed







2 years Kenya Sm # anti-measles IgG in 2-year-






1 year Uganda Sm No difference in post-vaccine
anti-measles IgG in 1-year-olds




Human 100 82% F 41 Kenya Sm No difference in anti-measles
IgG in HIV-infected adults
with Sm
�HGSIL = High grade squamous intraepithelial lesion
†Sm = S.mansoni; Sh = S. haematobium
https://doi.org/10.1371/journal.ppat.1009555.t009
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schistosome infection status [133]. Overall, these results suggest that active schistosome infec-
tion at the time of measles vaccination may impair anti-measles antibody response. Schisto-
some infection of the mother and schistosome infection acquired in adulthood seem to have
limited effects compared to the relatively stronger negative impact of schistosome infection
during childhood at the time of measles vaccination.
In summary, the 103 studies included in this review illustrate the breadth of data and the
complex impact of schistosomes on host anti-viral immunity. Ramifications on viral acquisi-
tion, virulence, and prevention are diverse and vary not only with host factors but also with
time-sensitive factors including the chronicity of the schistosome infection and elapsed time
since anti-schistosome treatment. In addition, interactions of schistosomes with viruses such
as HCV and HIV have been relatively well-studied, while only a few studies each have exam-
ined effects on other highly prevalent viruses including HPV, KSHV, and influenza.
Discussion
Studies included in this review consistently demonstrate that schistosome infection impairs
host immune response to some anti-viral vaccines, skews anti-viral immunity, and impacts,
possibly both positively and negatively, virulence of viral infections depending on the virus
and the site of pathology (Fig 2). With regards to viral prevention, active schistosome infection
seems to have mostly harmful effects by decreasing cellular and humoral responses to anti-
viral vaccinations and increasing risk for acquisition of certain viruses, including HIV and
KSHV. Once a virus has been acquired, schistosome coinfection induces Th2-dominant
immune responses that may exacerbate severity of some viral infection outcomes, particularly
hepatic damage by hepatidities and enteric viruses. However, in other viral infections includ-
ing HIV, HTLV-1, and respiratory viruses, schistosome infection may mitigate disease sever-
ity. Taken together, these findings urge comprehensive consideration of effects of co-
infections in endemic settings where viral and parasitic infections frequently converge, and
point to the need for further research (Table 10). This is especially important given the high
prevalence of schistosomiasis and helminth infections globally [134,135].
One of the most important potential public health impacts of our findings is that schistosome
infection decreases the cellular and humoral immune responses to several anti-viral immuniza-
tions including hepatitis B and measles. Poorer responses to poliovirus, rotavirus, and Ebola vac-
cines have been widely reported in low-income helminth-endemic countries [136–138]. For
example, oral rotavirus vaccine efficacy was 49% in Malawi versus 77% in higher-income coun-
tries [139], and the effects of schistosome infection are not known. Additional data are urgently
needed to determine whether treatment of schistosome infection prior to vaccine administration
could improve efficacy, as suggested by multiple studies in this review, and to optimize treatment
timing in order to maximize resolution of immune alterations and elimination of schistosome
eggs while limiting risk of schistosome re-infection. Coupling staged anti-schistosome treatment
and subsequent vaccination has potential to confer the dual benefit of lowering schistosome-
associated pathology and improving viral prevention. Schistosome treatment may improve
responses to bacterial vaccines such as tetanus and BCG as well [41,140,141].
Studies have also consistently reported that schistosome-hepatitis coinfection increases
severity of liver disease, and limited evidence suggests that anti-schistosome treatment could
prevent or alleviate liver fibrosis in schistosome-hepatitis co-infected persons. Therefore,
screening and treating for schistosome infection immediately in individuals diagnosed with
hepatitis viruses could avert severe liver disease.
While many studies demonstrate potential benefits of anti-schistosome treatment, others
invite further research in the context of some viral infections. Our synthesis of articles suggests
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that treatment of schistosome infection could increase HIV viral load in chronic HIV, and that
coinfection with schistosomes could reduce mortality in HIV-infected individuals. Both find-
ings are under-studied and lack statistical significance; further research is imperative to fully
understand their implications. Their existence, however, does suggest that mechanistic studies
on the potential beneficial effect of schistosome coinfection in chronic HIV are needed to pave
the way for novel immunoregulatory interventions.
Across an array of viruses and mammals, articles in this review consistently report Th1-do-
minant immune responses to viral mono-infection, versus Th2 and T regulatory-dominant
responses with schistosome-virus coinfection. These conserved immune responses to virus-
parasite infections may suggest strategies that could harness the beneficial effects of parasites
in some viral infections to improve clinical outcomes. The strong T regulatory component of
chronic schistosome infection may be particularly important, and studies in this review have
associated a T regulatory environment with decreased hepatic damage from HBV [36] and an
Fig 2. Chronic schistosome infection was associated with impaired anti-viral responses in some viral infections. In others, chronic schistosome infection appeared
to offer protection against viral infection attributable to T regulatory responses or to control of excessive Th1 inflammatory responses.
https://doi.org/10.1371/journal.ppat.1009555.g002
Table 10. Broad Priority Research Areas for Schistosome-Virus Coinfections.
Topic Priority Research Needs
Vaccines Vaccine efficacy in schistosome-endemic settings before schistosome infection is
acquired, or in LMIC settings in which schistosomes are endemic versus LMIC settings
in which schistosomes are not endemic
Effect of schistosome infection on other anti-viral vaccines, including rotavirus and
poliovirus
Optimal timing for praziquantel treatment prior to vaccination
Schistosome-Virus
Immunology
Precise timing of the dynamics of the human immune response to schistosome
infection, and to schistosome-virus coinfection




Antiviral effects of schistosome-induced host immunoregulatory molecules or cells
Antiviral effects of immunomodulatory parasite effector molecules
https://doi.org/10.1371/journal.ppat.1009555.t010
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HTLV-1 carrier rather than pro-inflammatory disease state [124]. T regs also have decreased
HIV-1 R5 virus susceptibility [142], which could limit cell-cell spread and slow HIV disease
progression. Other immune cell populations upregulated in chronic schistosome infection,
such as alternatively activated macrophages [109], and immunomodulatory parasite effector
molecules that incite Th2 and T regulatory responses (the subject of a recent comprehensive
review) [143], may have promising anti-viral therapeutic efficacy. Efforts to identify and test
immune cell products and schistosome immunomodulatory secretions should be included in
ongoing global research to prevent and treat viral infections. In addition, recent developments
in the area of controlled human schistosome challenge model [19] are expected to facilitate
more precise mapping of the host response throughout acute and chronic schistosome infec-
tion. Although these controlled schistosome infections use only male worms and therefore
may induce fewer Th2 and T reg responses because schistosome eggs are not produced, they
nonetheless provide a potent resource to understand immune responses to coinfections.
Effects of timing, duration, and dose of both schistosome infection and viral infections
could also influence the manifestation of schistosome-viral coinfection. Individuals may be
less likely to become infected with schistosome infection before acquiring viral infections that
are common in childhood, such as rotavirus. Conversely, they may be more likely to become
infected with schistosome infection during childhood before acquiring sexually transmitted
infections, such as HIV and HPV. Amount of time with untreated schistosome infection may
also impact the host response to coinfection. Thus, incorporating age prevalence curves of
viral infections in schistosome-endemic regions may be useful when considering public health
interventions to address coinfection.
This review has limitations. Only studies that documented active schistosome infection by
microscopy or antigen testing, but not by antibodies, were included due to antibodies remain-
ing positive after clearance of infection. This may have caused us to underestimate effects of
schistosome infection, because individuals who had cleared schistosome infections that previ-
ously affected their viral control would have been considered schistosome-uninfected. It also
could preclude capturing long-term immunological effects of past infections. Effects of envi-
ronmental, sociodemographic, and economic factors associated with schistosome infection
also could not be evaluated [144]. Further, only studies examining the impact of schistosome
infection on viral infections were included. Those assessing the impact of viruses on schisto-
some infection were beyond the scope of this review, as were those not published in English.
Finally, publication bias could have led to the non-publication of studies that showed no
impact of schistosomes on viral infections and thereby would not have been included.
In summary, this review highlights the major and complex effects of schistosome infection on
host response to viruses, encompassing viral acquisition, immune response, virulence, and pre-
vention. Considering the impact of parasitic infections on viral control could have important pub-
lic health implications for anti-viral vaccination strategies and control of viral infections globally.
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